CEP-9722 + gemcitabine + cisplatin

CEP-9722 + gemcitabine + cisplatin is a **combination regimen** of three agents used investigationally for the treatment of advanced solid tumors. **CEP-9722** is a small molecule prodrug of CEP-8983, a potent inhibitor of **poly(ADP-ribose) polymerase-1 (PARP-1)** and **PARP-2**, intended to potentiate the effects of DNA-damaging chemotherapies by inhibiting DNA repair mechanisms[3][1][5]. **Gemcitabine** is a nucleoside analog antimetabolite that inhibits DNA synthesis, and **cisplatin** is a platinum-based alkylating agent that induces DNA crosslinking, leading to cell death[2][4][6]. The gemcitabine + cisplatin combination is well-established as a synergistic and highly active regimen in multiple cancers, while the addition of CEP-9722 aims to further enhance antitumor efficacy through synthetic lethality. CEP-9722 was developed by Cephalon and later by Teva. This specific triple combination has been proposed in preclinical rationale and would primarily be indicated for cancers where PARP inhibition could enhance platinum/nucleoside chemotherapy, though no clinical trial data specifically for the triple combination is available.

Other names

CEP-9722 + gemcitabine + cisplatin